Journal: bioRxiv
Article Title: CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma
doi: 10.1101/2025.07.14.663986
Figure Lengend Snippet: A. Box plots showing construct-level Z-score averages for individual genes in the Mediator complex from a genome-wide CRISPR-Cas9 screen in Rh30 cells treated with DMSO (gray/black) or BI-1347 (blue/red) for 14 days (gray and blue) or 21 days (black and red). Genes are grouped by Mediator functional modules. B. Live cell proliferation assessed by Incucyte for BI-1347+/-sgCDK8 (red) and BI-1347+/-sgCCNC (blue). C. MA plot showing changes of CDK8 binding site assessed by CUT&RUN after 24 hrs of BI-1347 treatment. Significantly increased CDK8 peaks are highlighted in red; significantly decreased CDK8 peaks are highlighted in blue (padj<0.05, fold change>1.5 or <-1.5). D. Motif analysis of the regions with increased CDK8 DNA binding peaks from CUT&RUN analysis in Rh30 cells. E. Heatmaps showing chromatin occupancy of CDK8, CCNC, MED12, and MED13 at regions with upregulated SIX4 binding at 24 hrs of DMSO or BI-1347 treatment. F. IGV gene tracks showing the PRO-seq, CDK8, CCNC, MED12, and MED13 binding at the RUNX1 gene body and enhancer loci at indicated time points after BI-1347 treatment. G. Heatmaps of CDK8, CCNC, MED12, and MED13 CUT&RUN signal around PAX3::FOXO1-regulated enhancers before and after 24 hrs of BI-1347 treatment. H. IGV gene tracks showing the binding of CDK8, CCNC, MED12, and MED13 at a RUNX2 super enhancer cluster at indicated time points after BI-1347 treatment.
Article Snippet: The sgRNA was cloned into lentiCRISPR v2 containing Cas9 and puromycin resistance marker plasmid (Addgene, plasmid#52961). sgChr2.2: GGTGTGCGTATGAAGCAGTG sgCDK8-3: GAGGACCTGTTTGAATACGA sgCDK8-4: AGTGACTTCACCATTCCCCG sgTADA2B-1: GACAGGTGTGGTCTGTCACG sgTADA2B-3: GGGCGGCTGGACCAGTCGCG sgTAF5L-1: AAACAGTCCGAAGAGCACAG sgTAF5L-3: GCAGAAACATTCCATGGAAG sgSIX4-1: GCCTGCCCAGAAGTTCCGAG sgSIX4-2: GGATCAGGTACAACTCCACT
Techniques: Construct, Genome Wide, CRISPR, Functional Assay, Binding Assay